Research location
Ranica
Bergamo, Italy
Advertisement
Research activity in Ranica
Bergamo, ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 12 trials and 12 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ranica
12 linked trials · page 1 of 1Effects of Caloric Restriction in Obesity and Type 2 DiabetesNCT01930136 · 2013-05-01 · 1 site observation
COMPLETED
Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 DiabetesNCT01393808 · 2011-09-01 · 1 site observation
COMPLETED
Preventing Renal Functional Abnormalities With Calorie Restriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular RiskNCT01213212 · 2009-09-01 · 1 site observation
COMPLETED
Acetyl-L-Carnitine in Type 2 DiabetesNCT00984750 · 2008-04-01 · 1 site observation
COMPLETED
Preventing Microalbuminuria in Type 2 DiabetesNCT00503152 · 2007-05-01 · 1 site observation
COMPLETED
Preventing ESRD in Overt Nephropathy of Type 2 DiabetesNCT00494715 · 2007-05-01 · 1 site observation
COMPLETED
The Effects of Bindarit in Diabetic NephropathyNCT01109212 · 2007-03-01 · 1 site observation
COMPLETED
Ezetimibe and Simvastatin in Dyslipidemia of DiabetesNCT00157482 · 2005-01-01 · 1 site observation
COMPLETED
Acetylcarnitine and Insulin SensitivityNCT00393770 · 2004-02-01 · 1 site observation
COMPLETED
Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early NephropathyNCT00157508 · 2003-03-01 · 1 site observation
TERMINATED
Statins in Proteinuric NephropathiesNCT00199927 · 2003-03-01 · 1 site observation
COMPLETED
Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)NCT00157586 · 2002-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.